IBDEI0W9 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32450,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32450,1,3,0)
 ;;=3^Malig Neop Right Adrenal Gland,Secondary
 ;;^UTILITY(U,$J,358.3,32450,1,4,0)
 ;;=4^C79.71
 ;;^UTILITY(U,$J,358.3,32450,2)
 ;;=^5001356
 ;;^UTILITY(U,$J,358.3,32451,0)
 ;;=C78.01^^119^1564^155
 ;;^UTILITY(U,$J,358.3,32451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32451,1,3,0)
 ;;=3^Malig Neop Right Lung,Secondary
 ;;^UTILITY(U,$J,358.3,32451,1,4,0)
 ;;=4^C78.01
 ;;^UTILITY(U,$J,358.3,32451,2)
 ;;=^5001335
 ;;^UTILITY(U,$J,358.3,32452,0)
 ;;=C79.70^^119^1564^106
 ;;^UTILITY(U,$J,358.3,32452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32452,1,3,0)
 ;;=3^Malig Neop Adrenal Gland Unspec,Secondary
 ;;^UTILITY(U,$J,358.3,32452,1,4,0)
 ;;=4^C79.70
 ;;^UTILITY(U,$J,358.3,32452,2)
 ;;=^5001355
 ;;^UTILITY(U,$J,358.3,32453,0)
 ;;=C78.00^^119^1564^139
 ;;^UTILITY(U,$J,358.3,32453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32453,1,3,0)
 ;;=3^Malig Neop Lung Unspec,Secondary
 ;;^UTILITY(U,$J,358.3,32453,1,4,0)
 ;;=4^C78.00
 ;;^UTILITY(U,$J,358.3,32453,2)
 ;;=^5001334
 ;;^UTILITY(U,$J,358.3,32454,0)
 ;;=D57.1^^119^1564^182
 ;;^UTILITY(U,$J,358.3,32454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32454,1,3,0)
 ;;=3^Sickle-Cell Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,32454,1,4,0)
 ;;=4^D57.1
 ;;^UTILITY(U,$J,358.3,32454,2)
 ;;=^5002309
 ;;^UTILITY(U,$J,358.3,32455,0)
 ;;=D75.1^^119^1564^180
 ;;^UTILITY(U,$J,358.3,32455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32455,1,3,0)
 ;;=3^Polycythemia,Secondary
 ;;^UTILITY(U,$J,358.3,32455,1,4,0)
 ;;=4^D75.1
 ;;^UTILITY(U,$J,358.3,32455,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,32456,0)
 ;;=C90.30^^119^1564^183
 ;;^UTILITY(U,$J,358.3,32456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32456,1,3,0)
 ;;=3^Solitary Plasmacytoma,Not in Remission
 ;;^UTILITY(U,$J,358.3,32456,1,4,0)
 ;;=4^C90.30
 ;;^UTILITY(U,$J,358.3,32456,2)
 ;;=^5001759
 ;;^UTILITY(U,$J,358.3,32457,0)
 ;;=D56.3^^119^1564^184
 ;;^UTILITY(U,$J,358.3,32457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32457,1,3,0)
 ;;=3^Thalassemia Minor
 ;;^UTILITY(U,$J,358.3,32457,1,4,0)
 ;;=4^D56.3
 ;;^UTILITY(U,$J,358.3,32457,2)
 ;;=^340497
 ;;^UTILITY(U,$J,358.3,32458,0)
 ;;=D56.9^^119^1564^185
 ;;^UTILITY(U,$J,358.3,32458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32458,1,3,0)
 ;;=3^Thalassemia,Unspec
 ;;^UTILITY(U,$J,358.3,32458,1,4,0)
 ;;=4^D56.9
 ;;^UTILITY(U,$J,358.3,32458,2)
 ;;=^340606
 ;;^UTILITY(U,$J,358.3,32459,0)
 ;;=M31.1^^119^1564^187
 ;;^UTILITY(U,$J,358.3,32459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32459,1,3,0)
 ;;=3^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,32459,1,4,0)
 ;;=4^M31.1
 ;;^UTILITY(U,$J,358.3,32459,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,32460,0)
 ;;=D51.2^^119^1564^188
 ;;^UTILITY(U,$J,358.3,32460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32460,1,3,0)
 ;;=3^Transcobalamin II Deficiency
 ;;^UTILITY(U,$J,358.3,32460,1,4,0)
 ;;=4^D51.2
 ;;^UTILITY(U,$J,358.3,32460,2)
 ;;=^5002286
 ;;^UTILITY(U,$J,358.3,32461,0)
 ;;=D05.92^^119^1564^35
 ;;^UTILITY(U,$J,358.3,32461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32461,1,3,0)
 ;;=3^Carcinoma in Situ Left Breast,Unspec Type
 ;;^UTILITY(U,$J,358.3,32461,1,4,0)
 ;;=4^D05.92
 ;;^UTILITY(U,$J,358.3,32461,2)
 ;;=^5001937
 ;;^UTILITY(U,$J,358.3,32462,0)
 ;;=D05.91^^119^1564^37
 ;;^UTILITY(U,$J,358.3,32462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32462,1,3,0)
 ;;=3^Carcinoma in Situ Right Breast,Unspec Type
 ;;^UTILITY(U,$J,358.3,32462,1,4,0)
 ;;=4^D05.91
 ;;^UTILITY(U,$J,358.3,32462,2)
 ;;=^5001936
 ;;^UTILITY(U,$J,358.3,32463,0)
 ;;=D05.90^^119^1564^33
 ;;^UTILITY(U,$J,358.3,32463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32463,1,3,0)
 ;;=3^Carcinoma in Situ Breast Unspec,Unspec Type
 ;;^UTILITY(U,$J,358.3,32463,1,4,0)
 ;;=4^D05.90
 ;;^UTILITY(U,$J,358.3,32463,2)
 ;;=^5001935
 ;;^UTILITY(U,$J,358.3,32464,0)
 ;;=D51.0^^119^1564^189
 ;;^UTILITY(U,$J,358.3,32464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32464,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia d/t Intrinsic Factor Deficiency
 ;;^UTILITY(U,$J,358.3,32464,1,4,0)
 ;;=4^D51.0
 ;;^UTILITY(U,$J,358.3,32464,2)
 ;;=^5002284
 ;;^UTILITY(U,$J,358.3,32465,0)
 ;;=D51.1^^119^1564^190
 ;;^UTILITY(U,$J,358.3,32465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32465,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia d/t Selective Vit B12 Malabsorp w/ Proteinuria
 ;;^UTILITY(U,$J,358.3,32465,1,4,0)
 ;;=4^D51.1
 ;;^UTILITY(U,$J,358.3,32465,2)
 ;;=^5002285
 ;;^UTILITY(U,$J,358.3,32466,0)
 ;;=D51.9^^119^1564^192
 ;;^UTILITY(U,$J,358.3,32466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32466,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,32466,1,4,0)
 ;;=4^D51.9
 ;;^UTILITY(U,$J,358.3,32466,2)
 ;;=^5002289
 ;;^UTILITY(U,$J,358.3,32467,0)
 ;;=D68.0^^119^1564^194
 ;;^UTILITY(U,$J,358.3,32467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32467,1,3,0)
 ;;=3^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,32467,1,4,0)
 ;;=4^D68.0
 ;;^UTILITY(U,$J,358.3,32467,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,32468,0)
 ;;=C88.0^^119^1564^195
 ;;^UTILITY(U,$J,358.3,32468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32468,1,3,0)
 ;;=3^Waldenstrom Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,32468,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,32468,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,32469,0)
 ;;=C91.02^^119^1564^3
 ;;^UTILITY(U,$J,358.3,32469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32469,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,32469,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,32469,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,32470,0)
 ;;=C92.02^^119^1564^6
 ;;^UTILITY(U,$J,358.3,32470,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32470,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,32470,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,32470,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,32471,0)
 ;;=D09.3^^119^1564^45
 ;;^UTILITY(U,$J,358.3,32471,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32471,1,3,0)
 ;;=3^Carcinoma in Situ of Thyroid/Oth Endocrine Glands
 ;;^UTILITY(U,$J,358.3,32471,1,4,0)
 ;;=4^D09.3
 ;;^UTILITY(U,$J,358.3,32471,2)
 ;;=^5001955
 ;;^UTILITY(U,$J,358.3,32472,0)
 ;;=C22.0^^119^1564^86
 ;;^UTILITY(U,$J,358.3,32472,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32472,1,3,0)
 ;;=3^Hepatocellular Carcinoma
 ;;^UTILITY(U,$J,358.3,32472,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,32472,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,32473,0)
 ;;=C24.9^^119^1564^110
 ;;^UTILITY(U,$J,358.3,32473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32473,1,3,0)
 ;;=3^Malig Neop Biliary Tract,Unspec
 ;;^UTILITY(U,$J,358.3,32473,1,4,0)
 ;;=4^C24.9
 ;;^UTILITY(U,$J,358.3,32473,2)
 ;;=^5000942
 ;;^UTILITY(U,$J,358.3,32474,0)
 ;;=C50.922^^119^1564^134
 ;;^UTILITY(U,$J,358.3,32474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32474,1,3,0)
 ;;=3^Malig Neop Left Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,32474,1,4,0)
 ;;=4^C50.922
 ;;^UTILITY(U,$J,358.3,32474,2)
 ;;=^5133340
 ;;^UTILITY(U,$J,358.3,32475,0)
 ;;=C34.91^^119^1564^152
 ;;^UTILITY(U,$J,358.3,32475,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32475,1,3,0)
 ;;=3^Malig Neop Right Bronchus/Lung,Unspec Part
 ;;^UTILITY(U,$J,358.3,32475,1,4,0)
 ;;=4^C34.91
 ;;^UTILITY(U,$J,358.3,32475,2)
 ;;=^5000967
 ;;^UTILITY(U,$J,358.3,32476,0)
 ;;=C50.921^^119^1564^156
 ;;^UTILITY(U,$J,358.3,32476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32476,1,3,0)
 ;;=3^Malig Neop Right Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,32476,1,4,0)
 ;;=4^C50.921
 ;;^UTILITY(U,$J,358.3,32476,2)
 ;;=^5001198
 ;;^UTILITY(U,$J,358.3,32477,0)
 ;;=C90.02^^119^1564^167
 ;;^UTILITY(U,$J,358.3,32477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32477,1,3,0)
 ;;=3^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,32477,1,4,0)
 ;;=4^C90.02
